MedTrace Logo

Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair

NCT06238115 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2025-12-11

No results posted yet for this study

Summary

To explore whether administering tirofiban in stent-assisted coiling/flow diverting treatments for participants with unruptured intracranial aneurysms can reduce new ischemic lesions on postoperative DWI sequences compared to conventional dual antiplatelet therapy.

Conditions

  • Unruptured Intracranial Aneurysm
  • Flow Diverter
  • Stent-assisted Coiling
  • Thromboembolic Events

Interventions

DRUG

Tirofiban

Initial infusion of 0.4μg/kg body weight/minute over 30 minutes, followed by a continuous infusion of 0.1μg/kg body weight/minute for 24 hours.

DRUG

aspirin, clopidogrel

aspirin 100 mg/day, clopidogrel 75 mg/day

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Jing Jing · Beijing Tiantan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-04
Primary Completion
2025-10-09
Completion
2025-11-09

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06238115 on ClinicalTrials.gov